Ruxolitinib
Side effects
Options:
Show MedDRA Preferred Terms
|
Side effect
|
Data for drug
|
Placebo
|
Labels
|
|
|
1
|
2
|
3
|
|
Anaemia
|
very common, 11% - 96.1%
|
3.3% - 86.8%
|
x
|
x
|
x
|
|
Thrombocytopenia
|
very common, 3.9% - 69.8%
|
0% - 30.5%
|
x
|
x
|
x
|
|
Alanine aminotransferase increased
|
very common, 1.3% - 26.9%
|
|
|
x
|
x
|
|
Hypercholesterolaemia
|
very common, 0% - 17.4%
|
0.7%
|
|
x
|
x
|
|
Neutropenia
|
very common, 1.9% - 18.7%
|
0.7% - 4%
|
x
|
x
|
x
|
|
Contusion
|
very common, 0% - 65.3%
|
0% - 14.6%
|
x
|
x
|
x
|
|
Dizziness
|
very common, 0% - 18.1%
|
0% - 7.3%
|
x
|
x
|
x
|
|
Haemorrhage
|
very common, 2.3% - 32.6%
|
|
|
|
x
|
|
Epistaxis
|
very common, 2.3% - 13.3%
|
|
|
|
x
|
|
Haematuria
|
very common, 2.3% - 13.3%
|
|
|
|
x
|
|
Post procedural haemorrhage
|
very common, 2.3% - 13.3%
|
|
|
|
x
|
|
Headache
|
very common, 0% - 14.8%
|
0% - 5.3%
|
x
|
x
|
x
|
|
Urinary tract infection
|
very common, 0% - 14.4%
|
0.7% - 5.3%
|
x
|
x
|
x
|
|
Weight increased
|
common — 0% - 10%
|
0% - 1.3%
|
x
|
x
|
x
|
|
Gastrointestinal haemorrhage
|
common — 1.3% - 32.6%
|
|
|
|
x
|
|
Herpes zoster
|
common, 0% - 5.5%
|
0% - 0.7%
|
x
|
x
|
x
|
|
Flatulence
|
common, 0% - 5.2%
|
0% - 0.7%
|
x
|
|
x
|
|
Haemorrhage intracranial
|
common, 1%
|
|
|
|
x
|
|
Tuberculosis
|
uncommon — 0% - 1.4%
|
0%
|
|
x
|
x
|
|
Infection
|
|
|
|
x
|
x
|
|
Fatigue
|
|
|
|
x
|
x
|
|
Body temperature increased
|
|
|
|
x
|
x
|
|
Gastrointestinal disorder
|
|
|
|
x
|
x
|
|
Kidney infection
|
|
|
|
x
|
|
|
Plasma cell myeloma
|
|
|
|
x
|
|
|
Nervous system disorder
|
|
|
|
x
|
x
|
|
Night sweats
|
|
|
|
x
|
x
|
|
Pruritus
|
|
|
|
x
|
x
|
|
Weight decreased
|
|
|
|
x
|
x
|
|
Urosepsis
|
|
|
|
x
|
|
|
Bone pain
|
|
|
|
x
|
x
|
|
Malnutrition
|
|
|
|
x
|
x
|
|
Unspecified disorder of skin and subcutaneous tissue
|
|
|
|
x
|
|
|
Hepatobiliary disease
|
|
|
|
x
|
x
|
|
Blood pressure systolic increased
|
|
|
|
x
|
x
|
|
Prostate cancer
|
|
|
|
x
|
|
|
Infestation NOS
|
|
|
|
x
|
x
|
|
Blood and lymphatic system disorders
|
|
|
|
x
|
x
|
|
Myelosuppression
|
|
|
x
|
|
|
Indications
Information about indications was extracted from the indications and usage sections of the labels.
| Side effects: | 11 |
|---|
| Source: | FDA Structured Product Label |
|---|
| Side effects: | 31 |
|---|
| Source: | medicines.org.au |
|---|
| Side effects: | 33 |
|---|
| Source: | EMA |
|---|
Color scheme:
standard – alternative
|
|
|
100%
|
|
|
|
75%
|
|
|
|
50%
|
|
|
|
10%
|
|
|
|
frequent (1% to 100%)
|
|
|
|
infrequent (0.1% to 1%)
|
|
|
|
rare (<0.1%)
|
|
|
|
postmarketing
|
|
|
|
0%
|
|
|
|
no frequency information
|
|
|
|
not found on label
|
